Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
The no-reflow phenomenon after primary percutaneous coronary intervention (PCI) is not exceedingly uncommon and may lead to excess risks of adverse outcomes, including mortality, a recent study has found.
The efficacy and safety of the novel oral anticoagulant edoxaban relative to warfarin for stroke prophylaxis are consistent across the full range of systolic blood pressure (SBP) in high-risk patients with atrial fibrillation (AF), according to a posthoc analysis of the ENGAGE AF-TIMI 48 trial.
The use of implantable cardioverter-defibrillator (ICD) for the primary prevention of sudden death in heart failure with reduced ejection fraction (HFrEF) appears to be suboptimal, a study reports.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Type 2 diabetes (T2D) is an independent risk factor for all-cause dementia, with the greatest risk observed in patients who are insulin-dependent and obese, a recent study has found.
Weight- and blood pressure (BP) management strategies could promote the reversion from prediabetes to normoglycaemia, according to results of the SNAC-K* study.
Using statins may improve survival among elderly adults with rectal cancer, a recent study has shown.
Special Reports
At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Major trials have demonstrated the benefits of beta-blockers in the treatment of hypertension.1 At a recent symposium held during the Asian Pacific Society of Cardiology 2019 Congress in Manila, Philippines, experts discussed the latest guidelines on hypertension treatment, with a focus on the role of the 3rd generation beta-blocker, nebivolol. The symposium was chaired by Dr Dante D. Morales, Clinical Associate Professor at the University of the Philippines College of Medicine, and featured renowned cardiologists Prof Rafael R. Castillo and Dr Hyo Seung Ahn.
The cost of hospitalization for complications associatedwith influenza can be reduced significantly through theprevention of influenza infection.5 Cost savings mayincrease exponentially if one considers the control ofinfluenza outbreaks, especially in the aged care homesetting.
Renal cell carcinoma (RCC) is the most common primary tumour arising from the kidney, constituting approximately 80–85% of primary renal neoplasms. According to the Malaysian National Cancer Registry Report 2007–2011, RCC accounts for 62.8% of all kidney cancers nationwide. RCC typically occurs approximately 50% more commonly in men compared with women, and predominantly occurs in the sixth to eighth decade of life.
In an environment where children can interact openly, highly infectious diseases, such asinfluenza, have the potential to spread among childrenand those they come in contact with. Once infected,parents or siblings may have to take time off work or school to recover and to avoid spreading the disease to other healthy individuals.
Coenzyme Q10 (CoQ10, ubiquinone) is a fat-soluble, potent physiological antioxidant that is required for the production of cellular adenosine triphosphate (ATP). CoQ10 can be obtained through tissue synthesis and diet, and it has been widely studied in patients with cardiovascular (CV) risk factors. The effects of oral CoQ10 supplementation in different patient subgroups are presented here.
Conference Reports
The potent P2Y12 inhibitor prasugrel significantly reduced the incidence of death, myocardial infarction (MI), or stroke in patients with acute coronary syndrome (ACS) with or without ST-segment elevation (STE) compared with ticagrelor, according to the results of the ISAR-REACT* 5 trial presented at ESC Congress 2019. Moreover, the improved anti-ischaemic efficacy of prasugrel was not accompanied by an increased bleeding risk.
A single testing of cardiac troponin I using a high-sensitivity assay can effectively rule out myocardial infarction (MI) without compromising safety, according to the HiSTORIC* study presented at the ESC 2019 Congress.
A newly developed clinical risk score can identify patients with type 2 diabetes (T2D) at greatest risk for hospitalization for heart failure (HHF) who would derive the most benefit from treatment with dapagliflozin, according to a study presented at ESC 2019.
Prof Deepak Bhatt gives a rundown of the findings from THEMIS and THEMIS-PCI
Podcast: Prof Derek Chew explains the importance of a 1-hour troponin T protocol in suspected ACS as discussed in the RAPID-TnT trial
Podcast: Dr Shamir Mehta briefly discusses the clinical impact of findings from the COMPLETE trial
The incidence of cardiovascular disease (CVD)-related deaths is more common in low-income countries (LICs), while cancer-related deaths have increased in high-income countries (HICs) and some middle-income countries (MICs), according to new data from the PURE+ study presented at ESC 2019.
Multimedia
